SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase - Dependent cancers Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • HSP90 Heat-Shock Proteins
  • Neoplasms, Experimental
  • Receptor, ErbB-2

abstract

  • These results suggest that Hsp90 inhibition with SNX-2112 (delivered as a prodrug) may represent a promising therapeutic strategy for tumors whose growth and survival is dependent on Hsp90 clients.

publication date

  • January 2008

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC3203688

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-07-1667

PubMed ID

  • 18172276

Additional Document Info

start page

  • 240

end page

  • 8

volume

  • 14

number

  • 1